瑞舒伐他汀和阿托伐他汀治疗动脉粥样硬化性脑梗死伴高脂血症的成本-效果分析

Cost-effectiveness analysis of rosuvastatin and atorvastatin in the treatment of atherosclerotic cerebral infarction patients with hyperlipemia

目的:比较瑞舒伐他汀和阿托伐他汀治疗动脉粥样硬化性脑梗死伴高脂血症的有效性、安全性和成本-效果。方法:98例动脉粥样硬化性脑梗死伴高脂血症患者随机分为瑞舒伐他汀组(A组,10 mg/d)和阿托伐他汀组(B组,20 mg/d),每组各49例。治疗4周后观察两组降脂效果、并发症发生率和分析药物成本-效果。结果:治疗4周后,两组降脂效果、并发症发生率比较,差异均无统计学意义(P>0.05);A组成本-效果比明显低于B组。结论:瑞舒伐他汀和阿托伐他汀均为治疗动脉粥样硬化性脑梗死高脂血症安全有效的药物,但瑞舒伐他汀成本-效果比更优。

Objective To compare the efficacy,safety and cost - effectiveness of rosuvastatin and atorvastatin in the treatment of athero-sclerotic cerebral infarction（ACI）patients with hyperlipemia. Method 98 cases of ACI patients with hyperlipemia were randomly divided into rosuvastatin group（A group,10 mg/ d）and atorvastatin group（B group,20 mg/ d）. Each group contained 40 cases. After 4 weeks of the treatment,the lipid - lowering efficacy and the incidence rate of complication were observed,and the cost - effectiveness was analyzed between the two groups. Results After 4 weeks of the treatment,no significant differences were found in the lipid - lowering efficacy and the incidence rate of complication between the two groups（P ﹥ 0. 05）. However,the cost - effectiveness ratio in the A group was lower com-pared to the B group. Conclusion Rosuvastatin and atorvastatin in the treatment of hyperlipemia of ACI patients,which are all safe and ef-fective,but the cost - effectiveness ratio of rosuvastatin is better than atorvastatin.